Chris Gibson, Recursion CEO (Vaughn Ridley/Sportsfile for Web Summit via Getty Images)
Recursion discreetly culls a rare disease program to focus on cancer, pulls in $150M private placement
Recursion Pharmaceuticals quietly shut down work on one of its clinical programs Tuesday.
Researchers will end development on REC-3599, a drug candidate for GM2 gangliosidosis …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
